List of works - Maha Ayyoub

A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia

scientific article published on 01 June 2003

A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy

scientific article published on 01 November 2001

A peripheral circulating compartment of natural naive CD4 Tregs

scientific article

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

scientific article

A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells.

scientific article published on April 1999

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

scientific article published on April 2004

Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogs

scientific article published on 01 January 1998

Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

scientific article

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

scientific article

Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.

scientific article published on 22 December 2006

Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS

scientific article published on 27 May 2014

Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers

scientific article published on 29 July 2010

CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.

scientific article

CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.

scientific article

Classification of current anticancer immunotherapies

scientific article

Comment on "differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors"

scientific article published on 01 October 2014

Consensus nomenclature for CD8(+) T cell phenotypes in cancer

scientific article published on 25 February 2015

CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro

article

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

scientific article published on 01 August 2020

Decreased Binding of Peptides-MHC Class I (pMHC) Multimeric Complexes to CD8 Affects Their Binding Avidity for the TCR But Does Not Significantly Impact on pMHC/TCR Dissociation Rate ⬇️

scientific article published on May 15, 2003

Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells

scientific article published on 16 January 2015

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2

scientific article

Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1

scientific article published on 01 May 2005

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen

scientific article published on 24 October 2006

Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells.

scientific article published on 12 October 2011

Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

scientific article published on 12 September 2006

Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.

scientific article

HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine

scientific article published on 01 January 2009

Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors

scientific article

Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

scientific article published on 17 January 2012

Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. ⬇️

scholarly article

Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions

scientific article published on 25 September 2013

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

scientific article published in October 2005

Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.

scientific article published in June 2004

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles

scientific article

Immunological off-target effects of imatinib

scientific article

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

scientific article published on 29 January 2016

Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.

scientific article published in February 2009

Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.

scientific article

Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo

scientific article published on 01 July 2008

MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

scientific article published on 8 August 2012

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Microbiome and Anticancer Immunosurveillance

scientific article

Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells

scientific article published on 01 January 2019

Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity

scientific article published on 28 December 2015

Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.

scientific article

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

scientific article

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

scientific article

Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.

scientific article published in May 2006

Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.

scientific article published on 29 October 2014

Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T

scientific article published on 01 July 2006

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

scholarly article

Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

scientific article

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

scholarly article

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-ex

scientific article

Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire

scientific article published on 16 June 2009

List of works by Maha Ayyoub

A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia

A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy

A peripheral circulating compartment of natural naive CD4 Tregs

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells.

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogs

Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.

Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS

Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers

CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.

CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.

Classification of current anticancer immunotherapies

Comment on "differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors"

Consensus nomenclature for CD8(+) T cell phenotypes in cancer

CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

Decreased Binding of Peptides-MHC Class I (pMHC) Multimeric Complexes to CD8 Affects Their Binding Avidity for the TCR But Does Not Significantly Impact on pMHC/TCR Dissociation Rate ⬇️

Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2

Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen

Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells.

Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.

HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine

Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors

Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. ⬇️

Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles

Immunological off-target effects of imatinib

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.

Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.

Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo

MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Microbiome and Anticancer Immunosurveillance

Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells

Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity

Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.

Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.

Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-ex

Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire